基层心衰管理中NT-proBNP转诊超声心动图阈值的成本效果
本研究基于英国基层医疗疑似心衰患者,采用决策分析模型比较三种诊断策略:全部行超声心动图、ESC策略(NT-proBNP≥125 pg/mL)和NICE策略(NT-proBNP≥400 pg/mL)。结果显示NICE阈值较ESC阈值医疗成本更低且QALYs相近,但更低阈值增加心衰检出同时大幅增加非心衰患者的检查。成本效果对下游治疗模式假设敏感。
要点
- NICE阈值(≥400 pg/mL)较ESC阈值(≥125 pg/mL)成本更低且QALYs相近。
- 更低阈值增加心衰检出但大幅增加非心衰患者检查。
- 成本效果对下游治疗模式假设敏感,需关注真实世界处方。
核心结论
- 对于基层疑似心衰患者,NICE诊断阈值在病例检出与医疗资源使用之间实现了高效平衡。
- 更低阈值的成本效果对下游治疗模式假设敏感,评估诊断策略时需重视真实世界处方情况。
研究设计与样本
- 基于前瞻性REFER基层队列更新的决策分析模型,纳入当代心衰治疗和保留射血分数患者。
- 比较三种诊断策略:全部行超声心动图、ESC策略(NT-proBNP≥125 pg/mL)、NICE策略(NT-proBNP≥400 pg/mL)。
- 采用英国NHS视角,终身时间范围,成本和QALYs按每年3.5%贴现,并进行确定性和情景敏感性分析。
主要发现
- 基础病例中,NICE阈值(≥400 pg/mL)较ESC阈值(≥125 pg/mL)医疗成本更低且QALYs相近。
- 更低阈值增加心衰检出,但大幅增加非心衰患者的检查。
- 结果在大多数敏感性分析中稳健。
- 在假设所有治疗患者普遍使用利尿剂的情景下,ESC和全部超声策略较NICE产生额外QALYs且成本适度增加。
临床怎么用
- 基层疑似心衰患者可考虑采用NICE阈值(NT-proBNP≥400 pg/mL)决定是否转诊超声心动图,以平衡检出与资源使用。
- 评估更低阈值策略时需结合本地下游治疗模式,因成本效果受其影响。
局限性
- 分析基于模型假设和情景敏感性分析,存在结构和参数不确定性。
- 成本效果结果对下游治疗模式(如利尿剂使用)假设敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a key test in primary care to inform which people with possible heart failure (HF) are referred for specialist assessment and echocardiography. However, the impact of alternative NT-proBNP diagnostic thresholds on healthcare use, costs and patient outcomes remains uncertain. METHODS: We conducted a cost-effectiveness analysis of three diagnostic strategies for suspected HF in UK primary care: echocardiography for all, the European Society of Cardiology (ESC) strategy (NT-proBNP ≥125 pg/mL) and the National Institute for Health and Care Excellence (NICE) strategy (NT-proBNP ≥400 pg/mL). An updated decision-analytical model informed by the prospective REFerral for EchocaRdiogram (REFER) primary care cohort incorporated contemporary HF therapies and included patients with preserved ejection fraction. Analyses adopted a UK National Health Service perspective over a lifetime horizon. Costs and quality-adjusted life-years (QALYs) were discounted at 3.5% annually. Deterministic and scenario sensitivity analyses were undertaken to assess structural and parameter uncertainty. RESULTS: In the base-case, the NICE threshold (≥400 pg/mL) was associated with lower healthcare costs and similar QALYs compared with the ESC threshold (≥125 pg/mL). The lower threshold increased detection of HF but substantially increased investigations among patients without HF. Results were robust across most sensitivity analyses. Under a scenario assuming universal diuretic use among treated patients, ESC and echocardiography for all strategies generated additional QALYs at modest extra cost compared with NICE. CONCLUSION: For patients with suspected HF in primary care, the NICE diagnostic threshold represents an efficient balance between case detection and healthcare resource use. Cost-effectiveness of lower thresholds is sensitive to assumptions regarding downstream treatment patterns, highlighting the importance of real-world prescribing when evaluating diagnostic strategies.
引用
- Png, Tahsina, Jones, et al. Cost-effectiveness of N-terminal pro-B-type natriuretic peptide thresholds for echocardiography referral in primary care heart failure management. Heart. 2026. PMID: 42362366. doi:10.1136/heartjnl-2026-328059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。